Pelthos Therapeutics Inc. 8-K

What Happened

• Pelthos Therapeutics, Inc. (PTHS) filed a Current Report on Form 8‑K on March 19, 2026 to announce its financial results for the three months and the year ended December 31, 2025 and to provide an operational update. The company issued a press release summarizing those results, which is furnished as Exhibit 99.1 to the 8‑K and incorporated by reference. The filing also references a company presentation (Exhibit 99.2) and states the disclosure was made in compliance with Regulation FD.

Key Details

• Filing date: March 19, 2026 (Form 8‑K covering results for period ended December 31, 2025).
• Press release summarizing Q4 and full‑year 2025 results: furnished as Exhibit 99.1.
• Company presentation provided as Exhibit 99.2.
• Regulation FD disclosure (Item 7.01) indicates the information was publicly disclosed to ensure fair access.
• Form 8‑K signed by Francis Knuettel II, Chief Financial Officer, on behalf of the company.

Why It Matters

• This 8‑K signals that Pelthos publicly released its quarterly and annual financial results and operational update — key information investors use to assess recent performance and near‑term prospects.
• Investors should review the press release and presentation (Exhibits 99.1 and 99.2) for specific figures—revenue, net income/loss, cash position, and any guidance or program updates—since the 8‑K itself references those materials rather than listing detailed financial line items.
• Because the release was made under Regulation FD, the information was provided publicly (not selectively), which is important for market transparency and may affect the stock price once investors digest the detailed results.